June 1, 2017Open Access

Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies

Los puntos clave no están disponibles para este artículo en este momento.

Jintrolong PEG-rhGH at a dose of 0.2 mg/kg/week for 25 weeks is effective and safe for GHD treatment and is non-inferior to daily rhGH.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Luo et al. (Thu,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar

Ver artículo completo